Pfizer Inc. (NYSE:PFE) Holdings Lifted by Sterneck Capital Management LLC

Sterneck Capital Management LLC increased its holdings in Pfizer Inc. (NYSE:PFE) by 76.2% in the 4th quarter, Holdings Channel reports. The fund owned 32,630 shares of the biopharmaceutical company’s stock after purchasing an additional 14,107 shares during the period. Sterneck Capital Management LLC’s holdings in Pfizer were worth $866,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of PFE. Strategic Financial Concepts LLC purchased a new stake in Pfizer in the 2nd quarter worth approximately $38,000. Acadian Asset Management LLC raised its holdings in shares of Pfizer by 3.6% during the second quarter. Acadian Asset Management LLC now owns 326,990 shares of the biopharmaceutical company’s stock worth $9,144,000 after acquiring an additional 11,246 shares in the last quarter. Ausdal Financial Partners Inc. boosted its position in Pfizer by 7.0% during the second quarter. Ausdal Financial Partners Inc. now owns 14,967 shares of the biopharmaceutical company’s stock valued at $419,000 after purchasing an additional 982 shares during the last quarter. Quest Partners LLC purchased a new position in Pfizer in the second quarter valued at about $570,000. Finally, Private Management Group Inc. increased its position in Pfizer by 190.9% in the 2nd quarter. Private Management Group Inc. now owns 77,307 shares of the biopharmaceutical company’s stock worth $2,163,000 after purchasing an additional 50,728 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on PFE. Wolfe Research assumed coverage on Pfizer in a report on Friday, November 15th. They set an “underperform” rating and a $25.00 price target for the company. Sanford C. Bernstein initiated coverage on shares of Pfizer in a research note on Thursday, October 17th. They issued a “market perform” rating and a $32.00 target price for the company. Truist Financial dropped their price target on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research note on Wednesday, December 18th. StockNews.com lowered shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 20th. Finally, Bank of America reissued a “neutral” rating and set a $29.00 target price on shares of Pfizer in a research report on Tuesday, December 10th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $32.15.

Pfizer Trading Up 0.9 %

Pfizer stock opened at $27.12 on Wednesday. Pfizer Inc. has a 52 week low of $24.48 and a 52 week high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The firm has a market capitalization of $153.69 billion, a PE ratio of 36.65, a PEG ratio of 0.63 and a beta of 0.64. The business’s 50-day simple moving average is $26.27 and its 200-day simple moving average is $28.07.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, topping the consensus estimate of $0.64 by $0.42. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The company had revenue of $17.70 billion for the quarter, compared to the consensus estimate of $14.92 billion. During the same period in the previous year, the business posted ($0.17) EPS. The company’s revenue for the quarter was up 31.2% on a year-over-year basis. Equities research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be paid a dividend of $0.43 per share. This is a boost from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 annualized dividend and a yield of 6.34%. The ex-dividend date is Friday, January 24th. Pfizer’s dividend payout ratio is presently 232.43%.

Insider Buying and Selling at Pfizer

In other news, Director Scott Gottlieb purchased 1,000 shares of the business’s stock in a transaction on Wednesday, October 30th. The stock was purchased at an average price of $28.24 per share, with a total value of $28,240.00. Following the acquisition, the director now directly owns 10,000 shares in the company, valued at approximately $282,400. The trade was a 11.11 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 0.06% of the company’s stock.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.